Orchard Therapeutics plc financial data

Location
245 Hammersmith Road, 3 Rd Floor, London, United Kingdom
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2023 - Nov 13, 2023

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 303 % -36.3%
Quick Ratio 10.2 % +138%
Debt-to-equity 124 % +79.5%
Return On Assets -33.5 % +48.2%
Operating Margin -467 %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 228M shares +79.7%
Common Stock, Shares, Outstanding 227M shares +79.6%
Common Stock, Value, Issued 29.5M USD +80%
Weighted Average Number of Shares Outstanding, Basic 189M shares +48%
Weighted Average Number of Shares Outstanding, Diluted 189M shares +48%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 21.8M USD +9.09%
Research and Development Expense 72.8M USD -20.6%
Costs and Expenses 124M USD -16.3%
Operating Income (Loss) -102M USD +22.7%
Nonoperating Income (Expense) 29M USD +45.1%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -73.1M USD +59.5%
Income Tax Expense (Benefit) -140K USD +87.5%
Net Income (Loss) Attributable to Parent -72.9M USD +59.3%
Earnings Per Share, Basic 0 USD/shares +59.5%
Earnings Per Share, Diluted 0 USD/shares +59.5%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 23.5M USD -70.9%
Cash, Cash Equivalents, and Short-term Investments 125M USD -14.5%
Accounts Receivable, after Allowance for Credit Loss, Current 6.19M USD +46.2%
Inventory, Net 6.64M USD +184%
Assets, Current 154M USD -14.1%
Property, Plant and Equipment, Net 7.13M USD -8.62%
Operating Lease, Right-of-Use Asset 20M USD -13.5%
Intangible Assets, Net (Excluding Goodwill) 3.32M USD -4.76%
Other Assets, Noncurrent 10.3M USD -12.6%
Assets 202M USD -13.6%
Accounts Payable, Current 3.66M USD -43.8%
Employee-related Liabilities, Current 9.71M USD -3.61%
Liabilities, Current 49.4M USD -1.77%
Operating Lease, Liability, Noncurrent 16.7M USD -12.6%
Other Liabilities, Noncurrent 8.38M USD +26.3%
Liabilities 122M USD +10.6%
Accumulated Other Comprehensive Income (Loss), Net of Tax 22.6M USD -52.5%
Retained Earnings (Accumulated Deficit) -966M USD -8.17%
Stockholders' Equity Attributable to Parent 80.3M USD -35.1%
Liabilities and Equity 202M USD -13.6%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -29.5M USD -50.6%
Net Cash Provided by (Used in) Financing Activities 31.5M USD
Net Cash Provided by (Used in) Investing Activities -9.35M USD -137%
Common Stock, Shares, Issued 227M shares +79.6%
Common Stock, Par or Stated Value Per Share 0.1 GBP/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -6.94M USD -243%
Interest Paid, Excluding Capitalized Interest, Operating Activities 812K USD +39.8%
Payments to Acquire Property, Plant, and Equipment 514K USD +29.1%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -97.9M USD +27.6%
Operating Lease, Liability, Current 5.55M USD -11.2%
Deferred Income Tax Expense (Benefit) 242K USD -69.3%
Additional Paid in Capital 994M USD +4.34%
Amortization of Intangible Assets 300K USD 0%
Depreciation, Depletion and Amortization 643K USD -9.31%
Share-based Payment Arrangement, Expense 12.5M USD -28.3%
Interest Expense 3.8M USD +34.2%